NCT04851444View on ClinicalTrials.gov

A Study of SI-F019 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 30, 2021

Primary Completion Date

September 20, 2021

Study Completion Date

September 20, 2021

Conditions
Healthy
Interventions
DRUG

SI-F019

Single dose is administered IV.

Trial Locations (1)

201508

Shanghai Public Health Clinical Center Ethics Committee Approval Letter, Shanghai

All Listed Sponsors
collaborator

SystImmune Inc.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

NCT04851444 - A Study of SI-F019 in Healthy Participants | Biotech Hunter | Biotech Hunter